SPOTLIGHT: Celtic, Inspiration strike collaboration

Celtic Pharma and Inspiration Biopharmaceuticals announced a collaboration--valued at up to $35 million--intended to enhance the development of Inspiration's Factor IX for the treatment of Hemophilia B. Release

Suggested Articles

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.